BioCardia, Inc. BCDA
BioCardia, Inc. (Nasdaq: BCDA) is a cardio-renal-metabolic drug developer. Its lead program, CardiAMP Cell Therapy (BCDA-01), is in Phase 3 for Ischemic heart failure with reduced ejection fraction (HFrEF). Its next catalyst on record is CardiAMP Cell Therapy (HFrEF): Submission for approval in Japan (PMDA) (date not stated).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: CardiAMP Cell Therapy (HFrEF) — Submission for approval in Japan (PMDA) (date not stated). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| CardiAMP Cell Therapy HF II (BCDA-01) | Ischemic HFrEF | cell therapy | Phase 3 |
| CardiAMP Cell Therapy CMI (BCDA-02) | Chronic myocardial ischemia with refractory angina | cell therapy | Phase 3 |
| CardiALLO allogeneic MSC (BCDA-03) | Ischemic HFrEF | cell therapy | Phase 2 |
| PulmALLO allogeneic MSC | Acute respiratory distress syndrome | cell therapy | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.